Use of selective serotonin reuptake inhibitors and youth suicide: Making sense from a confusing story

Current Opinion in Psychiatry

Volumn 21, Issue 1, 2008, Pages 65-69

  Kutcher, Stan ^a,c   Gardner, David M ^b  

^a PAN AMERICAN HEALTH ORGANIZATION   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c IWK HEALTH CENTRE   (Canada)

Author keywords

Adolescents; Selective serotonin reuptake inhibitor; Suicidal behavior

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL TRIAL; DEPRESSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; LIFESPAN; MAJOR DEPRESSION; MEDICAL DECISION MAKING; OBSESSIVE COMPULSIVE DISORDER; PRESCRIPTION; PSYCHOTHERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIAL PSYCHOLOGY; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT;

ADOLESCENT; BIAS (EPIDEMIOLOGY); CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; SUICIDE, ATTEMPTED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 40349100144     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3282f29853     Document Type: Review

References (30)

1. AntidepressantsFacts. Children & SSRI's induced suicide. Antidepressants-Facts; 2004. http://www.antidepressantsfacts.com/children.htm. [Accessed 15 October 2007]
2. Kutcher S, Chehil S. Suicide risk management: a manual for health professionals. Oxford, UK: Blackwell Publishing Ltd; 2007. This publication provides an overview of suicide and a practical approach to clinical understanding and assessment of suicide risk.
3. Foley DL, Goldston DB, Costello EJ, Angold A. Proximal psychiatric risk factors for suicidality in youth: the Great Smoky Mountains Study. Arch Gen Psychiatry 2006; 63:1017-1024.
4. Brent DA, Mann JJ. Familial pathways to suicidal behaviour: understanding and preventing suicide among adolescents. N Engl J Med 2006; 355:2719-2721.
5. McKeown RE, Cuffe SP, Schulz RM. US suicide rates by age group, 1970-2002: an examination of recent trends. Am J Public Health 2006; 96:1744-1751.
6. Evans E, Hawton K, Rodham K, Deeks J. The prevalence of suicidal phenomena in adolescents: a systematic review of population-based studies. Suicide Life Threat Behav 2005; 35:239-250.
7. Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 2006; 94 (1-3):3-13.
8. Bosely S. 50,000 children taking antidepressants. The Guardian 2003, 20 September:1. http://www.guardian.co.uk/medicine/story/0,,1045921,00.html. [Accessed 17 October 2007]
9. Harris G. Doctors say they will cut antidepressant use. New York Times 2004, 16 September:1. http://www.nytimes.com/2004/09/16/health/16depress.html. [Accessed 17 October 2007]
10. Jureidini JN, Doecke CJ, Mansfield PR, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328:879-883.
11. Ramchandani P. A question of balance. Nature 2004; 430:401-402.
12. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63:332-339. This is a recent analysis from FDA authors on age and suicide related to antidepressant use.
13. United States Food and Drug Administration. Clinical review: relationship between antidepressant drugs and suicidality in adults. Department of Health and Human Service, Food and Drug Administration, Center for Drug Evaluation and Research. November 16, 2006; HFD-130:1, available online at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf. This is the most recent analytic review of this issue using FDA data.
14. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297:1683-1696. This critical and thoughtful meta-analysis of FDA data identifies weaknesses in the FDA analysis that led to the black box warning.
15. Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. Br J Psychiatry 2006; 189:393-398. This critical and thoughtful meta-analysis of CSM data shows how two different meta-analytical approaches gave two different results, raising the question about the policy decisions arising from the initial CSM analysis.
16. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807-820.
17. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60:978-982.
18. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006; 163:1898-1904.
19. Gould MS, Kalafat J, Harrismunfakh JL, Kleinman M. An evaluation of crisis hotline outcomes. Part 2: suicidal callers. Suicide Life Threat Behav 2007; 37:338-352.
20. Crowley P, Kilroe S, Burke S. Youth suicide prevention: an evidence briefing. Dublin, Ireland: Health Development Agency; 2004.
21. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164:884-891. This report demonstrates the effect of policy decisions from regulatory agencies on clinical care of young people.
22. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64:466-472.
23. Hamilton BE, Minino AM, Martin JA, et al. Annual summary of vital statistics: 2005. Pediatrics 2007; 119:345-360.
24. Brent D. Antidepressants and suicidal behavior: cause or cure? Am J Psychiatry 2007; 164:989-991. This is a thoughtful and critical overview of this issue from one of the most informed authors who has studied this topic.
25. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164:1356-1363. A study of the effects of the FDA policy decision on clinical care of young people pertaining to SSRI use is presented.
26. Gould MS, Greenberg T, Velting DM, Shaffer D. Youth suicide risk and preventive interventions: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 2003; 42:386-405. This is an excellent and critical systematic review of the evidence for the effectiveness of youth suicide prevention.
27. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163:41-47. This useful study illustrates the relationship between drop in suicide risk and the onset of antidepressant treatment.
28. Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 2007; 164:1029-1034.
29. Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005; 111:286-290.
30. Leon AC, Marzuk PM, Tardiff K, et al. Antidepressants and youth suicide in New York City, 1999-2002. J Am Acad Child Adolesc Psychiatry 2006; 45:1054-1058. This study of completed suicide and SSRI toxicology illustrates the lack of positive antidepressant post-mortem toxicology with completed youth suicide.